US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Toyota

206.73

-3.2000-1.52%

Post-market: 209.002.27+1.10%19:37 EDT

Volume:185.50K

Turnover:38.59M

Market Cap:269.37B

PE:11.44

High:210.16

Open:210.00

Low:206.31

Close:209.93

52wk High:248.90

52wk Low:155.00

Shares:1.30B

Float Shares:975.98M

Volume Ratio:0.67

T/O Rate:0.02%

Dividend:6.03

Dividend Rate:2.91%

EPS(TTM):18.07

EPS(LYR):24.01

ROE:10.03%

ROA:2.73%

PB:1.11

PE(LYR):8.61

Loading ...

Overview Company News Filings

Press Release: Kyntra Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

Press Release: Rafael Holdings Reports Second Quarter Fiscal 2026 Financial Results

Toyota turning to China for EVs is impacting more than sales

Press Release: Outlook Therapeutics Announces New $18.4 Million Non-Convertible Note Financing and Amendment to Existing Convertible Note

Press Release: Alto Neuroscience Reports Full Year 2025 Financial Results and Recent Business Highlights

Toyota Hit By Major US Recall Of 550,000 SUVs

Benzinga_recent_news

Press Release: NeOnc Technologies Appoints David Choi as Chief Accounting Officer

Press Release: AC Immune Reports Full Year 2025 Financial Results and Provides a Corporate Update

Press Release: Better Home & Finance Holding Company Announces Fourth Quarter 2025 Results

Press Release: Genenta, Evolving into Saentra Forge, Announces CEO's Appointment by the Italian Government to the Board of Guarantors of the Italian Academy at Columbia University

Press Release: Inside information: Timo Lehtonen takes on a new role at Bioretec as External Executive Advisor and steps down from the management team

Press Release: MindWalk Holdings Corp. Reports Q3 Fiscal 2026 Financial Results

Press Release: Cognyte to Announce Fourth Quarter and Full Year FYE26 Financial Results on March 25, 2026

Press Release: Theriva(TM) Biologics Reports Full-Year 2025 Operational Highlights and Financial Results

Press Release: MBX Biosciences Reports Fourth Quarter and Full-Year 2025 Financial Results and Recent Corporate Highlights

Press Release: Century Therapeutics Reports Full Year 2025 Financial Results and Business Updates

Press Release: Helus Pharma Strengthens Executive Team with Appointment of Jill Conwell as Chief People Officer

Press Release: HLS Therapeutics Announces Fiscal 2025 Financial Results

Press Release: MariMed Reports Fourth Quarter and Full Year 2025 Earnings

Press Release: SIR Royalty Income Fund Announces March 2026 Distribution

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Trading app for stocks, options & ETFs","description":"Invest in US, ASX, HK, China A-shares, ETFs & options with Tiger Brokers, Australia's trusted stock trading app!","keywords":"tiger brokers,tiger brokers au,tiger brokers australia,tiger trade,tiger trading,australia stock platform,US option,US stocks,stocks and options,australian trading platform,online broker australia,stock trading apps,mobile trading app,desktop trading,chess sponsored brokers,share trading platform","social":{"ogDescription":"Invest in US, ASX, HK, China A-shares, ETFs & options with Tiger Brokers, Australia's trusted stock trading app!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/TM/news?page=6"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"AUS","license":"TBAU","edition":"fundamental","symbol":"TM","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"TM\",,,,,undefined,":{"symbol":"TM","market":"US","secType":"STK","nameCN":"Toyota","latestPrice":206.73,"timestamp":1774641600000,"preClose":209.93,"halted":0,"volume":185497,"hourTrading":{"tag":"盘后","latestPrice":209.0023,"preClose":206.73,"latestTime":"19:37 EDT","volume":470,"amount":97490.5528,"timestamp":1774654639262,"change":2.2723,"changeRate":0.010992,"amplitude":0.010992},"delay":0,"changeRate":-0.01524317629686094,"floatShares":975975396,"shares":1303000000,"eps":18.073954,"marketStatus":"Market Closed","change":-3.2,"latestTime":"03-27 16:00:00 EDT","open":210,"high":210.16,"low":206.31,"amount":38589473.28639,"amplitude":0.018339,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":18.073954,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1774857600000},"marketStatusCode":7,"adr":1,"adrRate":10,"listingDate":938577600000,"exchange":"NYSE","adjPreClose":209.93,"dividendRate":0.029144,"preHourTrading":{"tag":"盘前","latestPrice":210,"preClose":209.93,"latestTime":"09:27 EDT","volume":462,"amount":97486.11641999999,"timestamp":1774618064561,"change":0.07,"changeRate":0.000333,"amplitude":0.017577},"postHourTrading":{"tag":"盘后","latestPrice":209.0023,"preClose":206.73,"latestTime":"19:37 EDT","volume":470,"amount":97490.5528,"timestamp":1774654639262,"change":2.2723,"changeRate":0.010992,"amplitude":0.010992},"volumeRatio":0.665697,"impliedVol":0.3562,"impliedVolPercentile":0.8924},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"TM\",,,,,undefined,":{"symbol":"TM","floatShares":975975396,"roa":"2.73%","roe":"10.03%","lyrEps":24.011171,"volumeRatio":0.665697,"shares":1303000000,"dividePrice":6.025,"high":210.16,"amplitude":0.018339,"preClose":209.93,"low":206.31,"week52Low":155,"pbRate":"1.11","psRate":"0.86","week52High":248.9,"institutionHeld":0.1694,"latestPrice":206.73,"eps":18.073954,"divideRate":0.029144,"volume":185497,"delay":0,"ttmEps":18.073954,"open":210,"prevYearClose":214.06,"prevWeekClose":205.02,"prevMonthClose":242.38,"prevQuarterClose":214.06,"fiveDayClose":205.02,"twentyDayClose":242.38,"sixtyDayClose":214.85,"dividendPayoutRate":1.3265738484248728,"dividendGrowthYears":0,"dividendGrowthRate":-0.5603196929755107,"fiveYearAvgDividendRate":0.022280239884563},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/TM\",params:#limit:5,,,undefined,":[{"date":"2026-02-06","symbol":"TM","type":"earning","reportTimeType":"pre","market":"US","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1770368400000,"name":null,"time":"Pre-Market","dateTimestamp":1770354000000,"actualEps":null},{"market":"US","date":"2025-11-05","symbol":"TM","fiscalQuarterEnding":"2025/09","expectedEps":null,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1762318800000,"reportTimeType":"pre","actualEps":4.85},{"market":"US","date":"2025-08-07","symbol":"TM","fiscalQuarterEnding":"2025/06","expectedEps":4.67,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1754539200000,"reportTimeType":"pre","actualEps":4.47},{"market":"US","date":"2025-05-08","symbol":"TM","fiscalQuarterEnding":"2025/03","expectedEps":2.92,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1746676800000,"reportTimeType":"pre","actualEps":3.39},{"market":"US","date":"2025-02-04","symbol":"TM","fiscalQuarterEnding":"2024/12","expectedEps":4.36,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1738645200000,"reportTimeType":"post","actualEps":6.81}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"TM\",market:\"US\",,,undefined,":[{"executeDate":"2016-03-29","recordDate":"2016-03-31","paymentDate":"2016-06-13","value":1.788575,"currency":"USD"},{"executeDate":"2016-09-28","recordDate":"2016-09-30","paymentDate":"2016-12-09","value":1.569363,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"TM\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.3333,"buy":0.3333,"hold":0.3333,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.3333,"analysts":6,"updateTime":1771041600000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/TM\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"TM","date":"2026-03-27","current":11.438006,"percent":0.90109,"low":5.801283,"twenty":8.530036,"median":9.821374,"eighty":10.80613,"high":15.732347,"avg":9.74356,"sd":1.778836,"marketCap":278207544709.07},"quantilePoints":[{"date":"2021-04-01","current":15.379939,"twenty":8.284318,"median":9.889724,"eighty":11.257693,"marketCap":212920926583.58},{"date":"2021-04-09","current":15.37081,"twenty":8.292991,"median":9.897121,"eighty":11.264065,"marketCap":214534379393.65},{"date":"2021-04-16","current":15.575315,"twenty":8.29484,"median":9.899657,"eighty":11.287872,"marketCap":219146543929.74},{"date":"2021-04-23","current":15.113351,"twenty":8.300069,"median":9.911472,"eighty":11.305336,"marketCap":214227339001.69},{"date":"2021-04-30","current":14.839459,"twenty":8.302037,"median":9.941679,"eighty":11.326666,"marketCap":207879909052.92},{"date":"2021-05-07","current":15.272208,"twenty":8.304174,"median":9.948661,"eighty":11.35442,"marketCap":215442030470.07},{"date":"2021-05-14","current":10.557371,"twenty":8.306161,"median":9.95703,"eighty":11.358063,"marketCap":216675223169.13},{"date":"2021-05-21","current":10.887366,"twenty":8.307068,"median":9.962049,"eighty":11.35442,"marketCap":224374963371},{"date":"2021-05-28","current":11.375511,"twenty":8.310743,"median":9.968205,"eighty":11.35442,"marketCap":232374614550.6},{"date":"2021-06-04","current":12.389158,"twenty":8.31455,"median":9.974649,"eighty":11.36039,"marketCap":254151605466.79},{"date":"2021-06-11","current":12.279575,"twenty":8.315756,"median":9.996262,"eighty":11.379801,"marketCap":251155532504.92},{"date":"2021-06-18","current":12.244707,"twenty":8.337475,"median":9.998633,"eighty":11.409941,"marketCap":249345297651.71},{"date":"2021-06-25","current":12.157656,"twenty":8.344714,"median":10.002518,"eighty":11.461692,"marketCap":246448337247.85},{"date":"2021-07-02","current":12.121858,"twenty":8.353161,"median":10.00669,"eighty":11.510411,"marketCap":244570067954.78},{"date":"2021-07-09","current":12.007361,"twenty":8.360278,"median":10.0111,"eighty":11.528452,"marketCap":244660766017.5},{"date":"2021-07-16","current":12.276127,"twenty":8.362541,"median":10.012625,"eighty":11.966324,"marketCap":250216586271.96},{"date":"2021-07-23","current":12.100682,"twenty":8.362783,"median":10.02974,"eighty":12.002976,"marketCap":245803841046.03},{"date":"2021-07-30","current":12.200225,"twenty":8.367639,"median":10.045351,"eighty":12.100682,"marketCap":249571241750.56},{"date":"2021-08-06","current":9.18363,"twenty":8.369812,"median":10.042583,"eighty":12.100682,"marketCap":248546674549.62},{"date":"2021-08-13","current":9.302183,"twenty":8.371983,"median":10.0275,"eighty":12.100682,"marketCap":252853601709.13},{"date":"2021-08-20","current":8.322023,"twenty":8.371983,"median":10.01247,"eighty":12.050911,"marketCap":226196301219.01},{"date":"2021-08-27","current":8.830772,"twenty":8.386407,"median":10.009884,"eighty":12.026178,"marketCap":239731757268.03},{"date":"2021-09-03","current":9.063413,"twenty":8.393326,"median":10.004604,"eighty":12.01051,"marketCap":246637389214.94},{"date":"2021-09-10","current":9.252002,"twenty":8.394908,"median":10.002518,"eighty":12.004072,"marketCap":251288150621.92},{"date":"2021-09-17","current":9.308671,"twenty":8.396048,"median":9.99775,"eighty":11.994408,"marketCap":252799709406.21},{"date":"2021-09-24","current":9.382992,"twenty":8.403792,"median":9.986261,"eighty":11.987415,"marketCap":252923794576.82},{"date":"2021-10-01","current":9.12927,"twenty":8.409387,"median":9.973917,"eighty":11.971261,"marketCap":245304629508.38},{"date":"2021-10-08","current":8.925056,"twenty":8.410028,"median":9.964878,"eighty":11.960601,"marketCap":237531091007.3},{"date":"2021-10-15","current":9.252262,"twenty":8.428607,"median":9.962049,"eighty":11.82452,"marketCap":241843777339.12},{"date":"2021-10-22","current":9.20585,"twenty":8.440923,"median":9.952345,"eighty":11.645716,"marketCap":241593442858.66},{"date":"2021-10-29","current":9.312598,"twenty":8.443706,"median":9.948053,"eighty":11.561919,"marketCap":243634285432.24},{"date":"2021-11-05","current":8.975461,"twenty":8.445805,"median":9.935016,"eighty":11.532678,"marketCap":248501922540.45},{"date":"2021-11-12","current":9.16732,"twenty":8.454705,"median":9.910445,"eighty":11.523333,"marketCap":252793124084.94},{"date":"2021-11-19","current":9.405489,"twenty":8.461877,"median":9.899061,"eighty":11.517377,"marketCap":259527117928.35},{"date":"2021-11-26","current":9.149677,"twenty":8.466559,"median":9.894628,"eighty":11.512447,"marketCap":253479623869.98},{"date":"2021-12-03","current":9.160058,"twenty":8.475021,"median":9.887521,"eighty":11.505169,"marketCap":254400083471.97},{"date":"2021-12-10","current":9.041096,"twenty":8.480033,"median":9.88412,"eighty":11.493229,"marketCap":250566573719.52},{"date":"2021-12-17","current":9.263599,"twenty":8.484548,"median":9.86767,"eighty":11.48171,"marketCap":256097965039.75},{"date":"2021-12-23","current":9.237163,"twenty":8.490174,"median":9.859408,"eighty":11.471221,"marketCap":253647768358.79},{"date":"2021-12-31","current":9.276817,"twenty":8.493551,"median":9.854997,"eighty":11.456034,"marketCap":253024211561.73},{"date":"2022-01-07","current":10.166827,"twenty":8.496303,"median":9.855048,"eighty":11.431774,"marketCap":276004685092.89},{"date":"2022-01-14","current":10.516828,"twenty":8.503793,"median":9.859806,"eighty":11.425102,"marketCap":290098154445},{"date":"2022-01-21","current":10.052591,"twenty":8.517735,"median":9.870881,"eighty":11.424469,"marketCap":277446097986.58},{"date":"2022-01-28","current":9.843575,"twenty":8.539835,"median":9.860203,"eighty":11.409941,"marketCap":268403226005.71},{"date":"2022-02-04","current":10.011773,"twenty":8.541824,"median":9.870881,"eighty":11.399135,"marketCap":272821257021.9},{"date":"2022-02-11","current":10.058874,"twenty":8.54339,"median":9.88412,"eighty":11.396131,"marketCap":268450027193.42},{"date":"2022-02-18","current":9.746486,"twenty":8.54339,"median":9.859806,"eighty":11.396131,"marketCap":261873033011.99},{"date":"2022-02-25","current":9.389472,"twenty":8.54339,"median":9.853459,"eighty":11.396131,"marketCap":251241883575.67},{"date":"2022-03-04","current":8.799364,"twenty":8.54339,"median":9.845856,"eighty":11.396131,"marketCap":237284744492.84},{"date":"2022-03-11","current":8.288067,"twenty":8.499307,"median":9.844533,"eighty":11.396131,"marketCap":218913247941.31},{"date":"2022-03-18","current":8.9986,"twenty":8.499307,"median":9.836624,"eighty":11.396131,"marketCap":233634975165.39},{"date":"2022-03-25","current":9.75293,"twenty":8.499307,"median":9.828189,"eighty":11.396131,"marketCap":247249672929.23},{"date":"2022-04-01","current":9.824217,"twenty":8.499307,"median":9.828189,"eighty":11.396131,"marketCap":247460850931.08},{"date":"2022-04-08","current":9.334918,"twenty":8.499307,"median":9.831145,"eighty":11.396131,"marketCap":232235123302.67},{"date":"2022-04-14","current":9.495289,"twenty":8.499307,"median":9.831145,"eighty":11.396131,"marketCap":233257145582.12},{"date":"2022-04-22","current":9.844986,"twenty":8.499307,"median":9.839797,"eighty":11.396131,"marketCap":236599907147.33},{"date":"2022-04-29","current":9.958582,"twenty":8.499307,"median":9.840723,"eighty":11.396131,"marketCap":237347675531.69},{"date":"2022-05-06","current":10.138999,"twenty":8.499307,"median":9.845088,"eighty":11.396131,"marketCap":240796093234.38},{"date":"2022-05-13","current":9.902689,"twenty":8.499307,"median":9.845841,"eighty":11.396131,"marketCap":218406153199.98},{"date":"2022-05-20","current":9.868957,"twenty":8.499307,"median":9.850202,"eighty":11.396131,"marketCap":219985877217.54},{"date":"2022-05-27","current":10.042435,"twenty":8.499307,"median":9.857177,"eighty":11.396131,"marketCap":225205518526.56},{"date":"2022-06-03","current":10.43276,"twenty":8.499307,"median":9.871524,"eighty":11.396131,"marketCap":227442854072.09},{"date":"2022-06-10","current":10.618285,"twenty":8.499307,"median":9.881378,"eighty":11.396131,"marketCap":225527280701.5},{"date":"2022-06-17","current":9.94124,"twenty":8.499307,"median":9.886852,"eighty":11.396131,"marketCap":209613208799.02},{"date":"2022-06-24","current":10.174953,"twenty":8.498306,"median":9.898721,"eighty":11.396882,"marketCap":214650672075.96},{"date":"2022-07-01","current":9.960515,"twenty":8.498306,"median":9.910445,"eighty":11.396882,"marketCap":209955949125.43},{"date":"2022-07-08","current":10.16347,"twenty":8.498306,"median":9.925171,"eighty":11.396882,"marketCap":212820567269.74},{"date":"2022-07-15","current":10.413825,"twenty":8.498306,"median":9.925171,"eighty":11.396882,"marketCap":214317007818.47},{"date":"2022-07-22","current":10.603999,"twenty":8.498306,"median":9.94124,"eighty":11.396882,"marketCap":222014152586.22},{"date":"2022-07-29","current":10.288648,"twenty":8.498306,"median":9.950148,"eighty":11.396882,"marketCap":219757471716.45},{"date":"2022-08-05","current":10.806112,"twenty":8.498306,"median":9.958582,"eighty":11.396882,"marketCap":214624780320.42},{"date":"2022-08-12","current":10.867192,"twenty":8.498306,"median":9.962049,"eighty":11.396882,"marketCap":218729696330.85},{"date":"2022-08-19","current":10.943542,"twenty":8.498306,"median":9.99775,"eighty":11.396882,"marketCap":214673171486.83},{"date":"2022-08-26","current":10.729761,"twenty":8.498306,"median":10.002981,"eighty":11.396882,"marketCap":210252561069.66},{"date":"2022-09-02","current":10.42945,"twenty":8.498306,"median":10.009884,"eighty":11.396882,"marketCap":200204255509.37},{"date":"2022-09-09","current":10.579606,"twenty":8.498306,"median":10.023176,"eighty":11.396882,"marketCap":199607069481.08},{"date":"2022-09-16","current":10.335285,"twenty":8.498306,"median":10.032798,"eighty":11.396882,"marketCap":194372829865.35},{"date":"2022-09-23","current":10.32256,"twenty":8.498306,"median":10.032798,"eighty":11.396882,"marketCap":193831215549.25},{"date":"2022-09-30","current":9.548877,"twenty":8.498306,"median":10.023176,"eighty":11.396882,"marketCap":177471819946.95},{"date":"2022-10-07","current":10.106181,"twenty":8.498306,"median":10.02316,"eighty":11.396882,"marketCap":187164770352.11},{"date":"2022-10-14","current":10.220706,"twenty":8.498306,"median":10.012625,"eighty":11.396882,"marketCap":185125554677.98},{"date":"2022-10-21","current":10.116361,"twenty":8.498306,"median":10.012625,"eighty":11.396882,"marketCap":183586764747.77},{"date":"2022-10-28","current":10.332686,"twenty":8.498306,"median":10.012625,"eighty":11.396882,"marketCap":188355275218.58},{"date":"2022-11-04","current":10.847885,"twenty":8.498306,"median":10.012625,"eighty":11.396882,"marketCap":184044729352.68},{"date":"2022-11-11","current":10.935324,"twenty":8.498306,"median":10.012625,"eighty":11.396882,"marketCap":196172673768.74},{"date":"2022-11-18","current":10.891604,"twenty":8.498306,"median":10.012625,"eighty":11.396882,"marketCap":194342479643.61},{"date":"2022-11-25","current":11.227697,"twenty":8.498306,"median":10.012625,"eighty":11.396882,"marketCap":201352566176.83},{"date":"2022-12-02","current":10.771376,"twenty":8.498306,"median":10.012625,"eighty":11.396882,"marketCap":198720186497.14},{"date":"2022-12-09","current":10.672344,"twenty":8.498306,"median":10.012625,"eighty":11.396882,"marketCap":195394464280.42},{"date":"2022-12-16","current":10.601341,"twenty":8.498306,"median":10.012625,"eighty":11.396882,"marketCap":193689705547.03},{"date":"2022-12-23","current":9.92954,"twenty":8.498306,"median":10.009884,"eighty":11.396882,"marketCap":186680586153.25},{"date":"2022-12-30","current":9.8995,"twenty":8.498306,"median":10.004188,"eighty":11.396882,"marketCap":187424120297.56},{"date":"2023-01-06","current":9.967773,"twenty":8.498306,"median":10.002518,"eighty":11.396882,"marketCap":187826513885.49},{"date":"2023-01-13","current":9.900927,"twenty":8.498306,"median":9.99775,"eighty":11.391839,"marketCap":193695001985.49},{"date":"2023-01-20","current":10.269042,"twenty":8.498306,"median":9.99775,"eighty":11.371547,"marketCap":197429750273.07},{"date":"2023-01-27","current":10.364479,"twenty":8.498306,"median":9.99775,"eighty":11.356276,"marketCap":199180241789.68},{"date":"2023-02-03","current":10.30012,"twenty":8.498306,"median":9.99775,"eighty":11.333641,"marketCap":196422447417.63},{"date":"2023-02-10","current":10.500354,"twenty":8.498306,"median":10.002518,"eighty":11.333641,"marketCap":194355374375.32},{"date":"2023-02-17","current":10.65962,"twenty":8.498306,"median":10.008162,"eighty":11.333641,"marketCap":192970903798.5},{"date":"2023-02-24","current":10.383001,"twenty":8.498306,"median":10.012625,"eighty":11.333641,"marketCap":185357918633.29},{"date":"2023-03-03","current":10.517526,"twenty":8.510764,"median":10.0275,"eighty":11.333641,"marketCap":187828381133.47},{"date":"2023-03-10","current":10.581708,"twenty":8.548174,"median":10.042435,"eighty":11.333641,"marketCap":190727411760.14},{"date":"2023-03-17","current":9.967791,"twenty":8.592191,"median":10.055161,"eighty":11.333641,"marketCap":183499755175.24},{"date":"2023-03-24","current":9.947037,"twenty":8.631375,"median":10.055161,"eighty":11.333641,"marketCap":185142028497.28},{"date":"2023-03-31","current":10.482303,"twenty":8.645153,"median":10.059123,"eighty":11.328108,"marketCap":191843639012.74},{"date":"2023-04-06","current":10.184004,"twenty":8.648723,"median":10.066202,"eighty":11.328108,"marketCap":188162070105.05},{"date":"2023-04-14","current":10.080853,"twenty":8.66463,"median":10.076589,"eighty":11.333641,"marketCap":185220967562.58},{"date":"2023-04-21","current":10.047399,"twenty":8.673795,"median":10.082108,"eighty":11.333641,"marketCap":182347845691.72},{"date":"2023-04-28","current":10.354062,"twenty":8.687916,"median":10.087954,"eighty":11.333641,"marketCap":188050875815.22},{"date":"2023-05-05","current":10.39588,"twenty":8.698992,"median":10.096155,"eighty":11.333641,"marketCap":188685008663.47},{"date":"2023-05-12","current":10.7467,"twenty":8.71352,"median":10.103167,"eighty":11.339175,"marketCap":196024816270.07},{"date":"2023-05-19","current":10.843542,"twenty":8.712564,"median":10.107669,"eighty":11.350241,"marketCap":191831714435.03},{"date":"2023-05-24","current":10.826941,"twenty":8.714955,"median":10.11015,"eighty":11.350241,"marketCap":190788985103.57},{"date":"2023-06-09","current":11.342728,"twenty":8.766683,"median":10.124788,"eighty":11.356641,"marketCap":200031894537.04},{"date":"2023-06-16","current":12.805147,"twenty":8.799234,"median":10.137578,"eighty":11.391839,"marketCap":223365019400.58},{"date":"2023-06-23","current":12.161019,"twenty":8.828227,"median":10.143938,"eighty":11.422196,"marketCap":208670959088.58},{"date":"2023-06-29","current":12.691802,"twenty":8.864323,"median":10.150966,"eighty":11.489152,"marketCap":215086680971.05},{"date":"2023-07-03","current":12.857672,"twenty":8.872176,"median":10.160675,"eighty":11.502548,"marketCap":218018238631.84},{"date":"2023-07-12","current":12.147683,"twenty":8.918218,"median":10.163979,"eighty":11.779334,"marketCap":215254189834.62},{"date":"2023-07-20","current":12.639559,"twenty":8.96426,"median":10.167277,"eighty":11.966324,"marketCap":220786122927.06},{"date":"2023-07-28","current":12.766673,"twenty":9.010002,"median":10.174767,"eighty":12.00188,"marketCap":221871351348.02},{"date":"2023-08-04","current":10.899958,"twenty":9.031492,"median":10.17782,"eighty":12.007361,"marketCap":231851878614.13},{"date":"2023-08-11","current":10.861948,"twenty":9.04236,"median":10.184004,"eighty":12.007361,"marketCap":227593958068.73},{"date":"2023-08-18","current":10.504206,"twenty":9.078146,"median":10.189579,"eighty":12.007361,"marketCap":217607210721.31},{"date":"2023-08-25","current":10.709908,"twenty":9.10278,"median":10.197801,"eighty":12.007361,"marketCap":222436604173.45},{"date":"2023-09-01","current":11.266644,"twenty":9.122869,"median":10.217604,"eighty":12.007361,"marketCap":234091178799.61},{"date":"2023-09-08","current":11.632383,"twenty":9.129306,"median":10.223034,"eighty":12.007361,"marketCap":239062167551.94},{"date":"2023-09-15","current":12.608824,"twenty":9.149677,"median":10.231608,"eighty":12.038468,"marketCap":259256210611.1},{"date":"2023-09-22","current":12.461352,"twenty":9.160246,"median":10.253921,"eighty":12.102922,"marketCap":255740860659.18},{"date":"2023-09-29","current":11.965312,"twenty":9.176462,"median":10.263466,"eighty":12.122846,"marketCap":242410597101.79},{"date":"2023-10-05","current":11.567214,"twenty":9.18527,"median":10.271329,"eighty":12.123833,"marketCap":235551857382.08},{"date":"2023-10-12","current":12.23713,"twenty":9.197232,"median":10.271457,"eighty":12.139596,"marketCap":247225582426.59},{"date":"2023-10-20","current":11.687799,"twenty":9.211776,"median":10.276468,"eighty":12.142831,"marketCap":235929020292.45},{"date":"2023-11-03","current":9.638628,"twenty":9.235475,"median":10.293128,"eighty":12.148482,"marketCap":247832080640.27},{"date":"2023-11-10","current":9.779528,"twenty":9.258366,"median":10.293128,"eighty":12.148482,"marketCap":250599077838.42},{"date":"2023-11-17","current":10.091789,"twenty":9.275495,"median":10.293128,"eighty":12.148482,"marketCap":259396028596.42},{"date":"2023-11-24","current":9.779528,"twenty":9.28243,"median":10.293128,"eighty":12.148482,"marketCap":252923781896.85},{"date":"2023-12-01","current":9.884197,"twenty":9.289465,"median":10.293128,"eighty":12.148482,"marketCap":258764509700.73},{"date":"2023-12-08","current":9.347202,"twenty":9.298314,"median":10.288648,"eighty":12.148216,"marketCap":250910555795.92},{"date":"2023-12-15","current":9.068233,"twenty":9.30405,"median":10.293128,"eighty":12.148482,"marketCap":247803779364.67},{"date":"2023-12-21","current":8.848545,"twenty":9.30405,"median":10.293128,"eighty":12.148482,"marketCap":238192449604.09},{"date":"2023-12-29","current":9.033362,"twenty":9.307273,"median":10.297791,"eighty":12.149015,"marketCap":247750139359.73},{"date":"2024-01-05","current":9.420431,"twenty":9.308671,"median":10.297973,"eighty":12.150743,"marketCap":252256823254.4},{"date":"2024-01-12","current":9.887005,"twenty":9.327923,"median":10.297973,"eighty":12.150743,"marketCap":261924877051.17},{"date":"2024-01-19","current":10.322632,"twenty":9.349294,"median":10.300942,"eighty":12.152471,"marketCap":269866492565.03},{"date":"2024-01-26","current":10.080423,"twenty":9.369845,"median":10.312289,"eighty":12.150743,"marketCap":264286074026.99},{"date":"2024-02-02","current":10.28604,"twenty":9.388706,"median":10.31924,"eighty":12.150743,"marketCap":272255603890.7},{"date":"2024-02-09","current":9.957996,"twenty":9.394266,"median":10.32256,"eighty":12.150743,"marketCap":299960785015.74},{"date":"2024-02-16","current":10.230695,"twenty":9.394266,"median":10.32256,"eighty":12.150743,"marketCap":306411060067.22},{"date":"2024-02-23","current":10.551341,"twenty":9.394266,"median":10.323577,"eighty":12.150743,"marketCap":315378380929.65},{"date":"2024-03-01","current":11.027814,"twenty":9.394278,"median":10.33109,"eighty":12.149015,"marketCap":331146760105.98},{"date":"2024-03-08","current":10.813788,"twenty":9.394278,"median":10.335285,"eighty":12.149015,"marketCap":328807996181.04},{"date":"2024-03-15","current":10.448336,"twenty":9.394278,"median":10.34246,"eighty":12.149015,"marketCap":317352794924.37},{"date":"2024-03-22","current":11.598612,"twenty":9.394278,"median":10.355684,"eighty":12.149015,"marketCap":344082353343.51},{"date":"2024-03-28","current":11.400908,"twenty":9.394278,"median":10.3593,"eighty":12.149015,"marketCap":339062320000.54},{"date":"2024-04-05","current":10.837354,"twenty":9.394266,"median":10.37261,"eighty":12.150743,"marketCap":321490532674.96},{"date":"2024-04-12","current":11.28055,"twenty":9.394266,"median":10.377412,"eighty":12.150743,"marketCap":331086520232.15},{"date":"2024-04-19","current":10.54688,"twenty":9.394266,"median":10.38364,"eighty":12.150743,"marketCap":306968136269.85},{"date":"2024-04-26","current":10.510945,"twenty":9.394278,"median":10.389205,"eighty":12.149015,"marketCap":304094877924.26},{"date":"2024-05-03","current":10.72356,"twenty":9.394278,"median":10.39588,"eighty":12.149015,"marketCap":313701286943.33},{"date":"2024-05-10","current":8.968812,"twenty":9.394219,"median":10.405631,"eighty":12.149015,"marketCap":284988352069.93},{"date":"2024-05-17","current":9.35894,"twenty":9.370205,"median":10.405631,"eighty":12.149015,"marketCap":298070569595.92},{"date":"2024-05-24","current":9.241817,"twenty":9.361646,"median":10.405631,"eighty":12.149015,"marketCap":290894869344.83},{"date":"2024-05-31","current":9.263607,"twenty":9.350689,"median":10.405631,"eighty":12.149015,"marketCap":292373544175.41},{"date":"2024-06-07","current":8.767878,"twenty":9.330368,"median":10.405631,"eighty":12.149015,"marketCap":277873277699.88},{"date":"2024-06-14","current":8.487327,"twenty":9.308671,"median":10.405631,"eighty":12.149015,"marketCap":267473488691.17},{"date":"2024-06-21","current":8.372928,"twenty":9.301945,"median":10.408148,"eighty":12.150743,"marketCap":260910138589.3},{"date":"2024-06-28","current":8.961267,"twenty":9.298847,"median":10.412275,"eighty":12.157656,"marketCap":275771302935.71},{"date":"2024-07-05","current":9.040257,"twenty":9.291914,"median":10.412275,"eighty":12.157656,"marketCap":277390762189.75},{"date":"2024-07-12","current":8.917686,"twenty":9.282674,"median":10.412275,"eighty":12.157656,"marketCap":278137816190.97},{"date":"2024-07-15","current":8.917686,"twenty":9.28243,"median":10.412275,"eighty":12.157656,"marketCap":279355354112.01},{"date":"2024-08-02","current":7.041317,"twenty":9.276817,"median":10.39588,"eighty":12.184402,"marketCap":231924591714.35},{"date":"2024-08-09","current":6.637283,"twenty":9.265654,"median":10.39588,"eighty":12.184402,"marketCap":223881488426.31},{"date":"2024-08-16","current":7.442706,"twenty":9.252106,"median":10.39588,"eighty":12.184402,"marketCap":248253869142.74},{"date":"2024-08-23","current":7.273214,"twenty":9.233928,"median":10.39588,"eighty":12.184402,"marketCap":247232647793.85},{"date":"2024-08-30","current":7.483383,"twenty":9.22424,"median":10.39588,"eighty":12.184402,"marketCap":255852831018.33},{"date":"2024-09-06","current":7.003384,"twenty":9.219097,"median":10.39588,"eighty":12.184402,"marketCap":242110054996.92},{"date":"2024-09-13","current":6.657621,"twenty":9.20585,"median":10.390862,"eighty":12.184402,"marketCap":232274731105.64},{"date":"2024-09-20","current":7.143045,"twenty":9.191896,"median":10.382809,"eighty":12.184402,"marketCap":248538318454.32},{"date":"2024-09-27","current":7.44525,"twenty":9.18363,"median":10.373181,"eighty":12.184402,"marketCap":255458190614.14},{"date":"2024-10-04","current":6.997426,"twenty":9.168808,"median":10.358804,"eighty":12.184402,"marketCap":236830385239.74},{"date":"2024-10-11","current":6.932484,"twenty":9.1553,"median":10.354854,"eighty":12.184402,"marketCap":231904929554.32},{"date":"2024-10-18","current":6.757684,"twenty":9.141533,"median":10.335285,"eighty":12.184402,"marketCap":223778731168.75},{"date":"2024-10-25","current":6.883439,"twenty":9.129284,"median":10.329287,"eighty":12.184402,"marketCap":225048774919.69},{"date":"2024-10-31","current":7.101856,"twenty":9.122712,"median":10.322596,"eighty":12.184402,"marketCap":231437178743.57},{"date":"2024-11-08","current":8.200075,"twenty":9.102264,"median":10.31392,"eighty":12.18547,"marketCap":228195126660.03},{"date":"2024-11-15","current":8.327889,"twenty":9.082145,"median":10.30012,"eighty":12.18547,"marketCap":227851679690.47},{"date":"2024-11-22","current":8.206235,"twenty":9.064377,"median":10.276611,"eighty":12.18547,"marketCap":226334810049.29},{"date":"2024-11-29","current":7.858213,"twenty":9.045208,"median":10.270427,"eighty":12.18547,"marketCap":221081895555.64},{"date":"2024-12-06","current":8.096901,"twenty":9.033515,"median":10.254464,"eighty":12.18547,"marketCap":229868025198.21},{"date":"2024-12-13","current":8.30787,"twenty":9.021772,"median":10.22796,"eighty":12.18547,"marketCap":232643820156.81},{"date":"2024-12-20","current":8.535778,"twenty":9.007394,"median":10.218161,"eighty":12.18547,"marketCap":230746247381.81},{"date":"2024-12-27","current":9.818531,"twenty":8.9986,"median":10.200346,"eighty":12.18547,"marketCap":264870066494.9},{"date":"2025-01-03","current":9.675442,"twenty":8.9986,"median":10.189579,"eighty":12.18547,"marketCap":261830247114.05},{"date":"2025-01-10","current":9.007894,"twenty":8.9986,"median":10.180013,"eighty":12.186538,"marketCap":243092635183.17},{"date":"2025-01-17","current":8.565487,"twenty":8.967107,"median":10.171523,"eighty":12.186538,"marketCap":235114492848.26},{"date":"2025-01-24","current":8.855817,"twenty":8.961267,"median":10.165658,"eighty":12.186538,"marketCap":242008458741.27},{"date":"2025-01-31","current":9.135393,"twenty":8.957202,"median":10.141395,"eighty":12.186538,"marketCap":252298057008.53},{"date":"2025-02-07","current":7.246926,"twenty":8.947648,"median":10.131987,"eighty":12.186538,"marketCap":243295591170.03},{"date":"2025-02-14","current":7.195611,"twenty":8.947648,"median":10.131987,"eighty":12.186538,"marketCap":239862178438.66},{"date":"2025-02-21","current":6.942886,"twenty":8.947648,"median":10.131987,"eighty":12.186538,"marketCap":236481636207.77},{"date":"2025-02-28","current":6.899269,"twenty":8.947648,"median":10.131987,"eighty":12.186538,"marketCap":234522781422.4},{"date":"2025-03-07","current":7.181905,"twenty":8.952256,"median":10.133998,"eighty":12.187463,"marketCap":247050876999.6},{"date":"2025-03-14","current":7.03714,"twenty":8.952256,"median":10.133998,"eighty":12.187463,"marketCap":242985940371.29},{"date":"2025-03-21","current":7.288238,"twenty":8.952256,"median":10.133998,"eighty":12.187463,"marketCap":249726240097.54},{"date":"2025-03-28","current":6.919278,"twenty":8.952256,"median":10.133998,"eighty":12.187463,"marketCap":233662092178.64},{"date":"2025-04-04","current":6.162183,"twenty":8.952256,"median":10.133998,"eighty":12.187463,"marketCap":215308987506.32},{"date":"2025-04-11","current":6.194178,"twenty":8.947648,"median":10.131987,"eighty":12.186538,"marketCap":218785571059.41},{"date":"2025-04-17","current":6.395105,"twenty":8.947648,"median":10.131987,"eighty":12.186538,"marketCap":229351374300.22},{"date":"2025-04-25","current":6.885264,"twenty":8.952256,"median":10.133998,"eighty":12.187463,"marketCap":246031968895.36},{"date":"2025-05-02","current":7.106778,"twenty":8.952256,"median":10.133998,"eighty":12.187463,"marketCap":249213599815.24},{"date":"2025-05-09","current":7.437943,"twenty":8.952256,"median":10.133998,"eighty":12.187463,"marketCap":244240265458.25},{"date":"2025-05-16","current":7.227345,"twenty":8.952256,"median":10.133998,"eighty":12.187463,"marketCap":236183901810.15},{"date":"2025-05-23","current":7.175379,"twenty":8.952256,"median":10.133998,"eighty":12.187463,"marketCap":237806187933.75},{"date":"2025-05-30","current":7.573327,"twenty":8.942194,"median":10.133998,"eighty":12.187463,"marketCap":250196249736.93},{"date":"2025-06-06","current":7.253328,"twenty":8.917141,"median":10.133998,"eighty":12.187463,"marketCap":240568591737.01},{"date":"2025-06-13","current":6.988029,"twenty":8.896562,"median":10.133998,"eighty":12.187463,"marketCap":231679210496.78},{"date":"2025-06-20","current":6.844439,"twenty":8.874332,"median":10.13429,"eighty":12.188387,"marketCap":223775204425.4},{"date":"2025-06-27","current":6.911447,"twenty":8.854761,"median":10.13429,"eighty":12.188387,"marketCap":227922345870.74},{"date":"2025-07-03","current":6.869054,"twenty":8.832895,"median":10.13429,"eighty":12.188387,"marketCap":225981638453.82},{"date":"2025-07-11","current":6.859481,"twenty":8.818202,"median":10.13429,"eighty":12.188387,"marketCap":223205689863.85},{"date":"2025-07-18","current":6.881362,"twenty":8.755943,"median":10.13429,"eighty":12.188387,"marketCap":220798069049.78},{"date":"2025-07-25","current":7.622558,"twenty":8.72522,"median":10.13429,"eighty":12.188387,"marketCap":247481668440},{"date":"2025-08-01","current":7.451617,"twenty":8.675821,"median":10.13429,"eighty":12.188387,"marketCap":235893267000.58},{"date":"2025-08-08","current":8.457965,"twenty":8.591357,"median":10.129531,"eighty":12.169091,"marketCap":245167376130.22},{"date":"2025-08-15","current":8.705024,"twenty":8.549275,"median":10.11015,"eighty":12.131916,"marketCap":251818018551.78},{"date":"2025-08-22","current":8.976484,"twenty":8.549275,"median":10.097345,"eighty":12.100682,"marketCap":258887369440.83},{"date":"2025-08-29","current":8.762976,"twenty":8.549275,"median":10.086949,"eighty":12.029251,"marketCap":254691051237.66},{"date":"2025-09-05","current":9.035961,"twenty":8.546128,"median":10.073721,"eighty":11.996899,"marketCap":259717499918.27},{"date":"2025-09-12","current":8.811778,"twenty":8.549275,"median":10.058874,"eighty":11.962956,"marketCap":255832771462.94},{"date":"2025-09-19","current":8.915482,"twenty":8.549275,"median":10.046043,"eighty":11.826465,"marketCap":257529541517.41},{"date":"2025-09-26","current":9.057312,"twenty":8.549275,"median":10.036139,"eighty":11.659912,"marketCap":258443271914.81},{"date":"2025-10-03","current":8.660797,"twenty":8.549275,"median":10.023168,"eighty":11.568256,"marketCap":251082563433.89},{"date":"2025-10-10","current":8.840754,"twenty":8.549275,"median":10.003584,"eighty":11.452811,"marketCap":246650808761.59},{"date":"2025-10-17","current":8.947508,"twenty":8.549275,"median":9.979594,"eighty":11.337752,"marketCap":253592982643.91},{"date":"2025-10-24","current":9.537705,"twenty":8.549275,"median":9.967773,"eighty":11.28055,"marketCap":266870625343.7},{"date":"2025-10-31","current":9.571256,"twenty":8.549275,"median":9.958289,"eighty":11.209109,"marketCap":265411053652.74},{"date":"2025-11-07","current":8.774478,"twenty":8.549275,"median":9.945195,"eighty":11.180772,"marketCap":265409055839.35},{"date":"2025-11-14","current":8.948954,"twenty":8.549275,"median":9.929547,"eighty":11.080493,"marketCap":268538147702.6},{"date":"2025-11-21","current":8.715381,"twenty":8.538212,"median":9.925171,"eighty":11.0091,"marketCap":256286827122.06},{"date":"2025-11-28","current":8.81669,"twenty":8.538212,"median":9.90985,"eighty":10.993116,"marketCap":261289943005.86},{"date":"2025-12-05","current":8.532462,"twenty":8.530036,"median":9.8995,"eighty":10.967688,"marketCap":255346933696.96},{"date":"2025-12-12","current":9.174085,"twenty":8.530036,"median":9.882026,"eighty":10.944626,"marketCap":273667846563.7},{"date":"2025-12-19","current":9.635604,"twenty":8.530036,"median":9.877292,"eighty":10.923873,"marketCap":287107870130.45},{"date":"2025-12-26","current":9.511782,"twenty":8.530036,"median":9.865354,"eighty":10.903594,"marketCap":282368379100.45},{"date":"2026-01-02","current":9.444242,"twenty":8.530036,"median":9.850316,"eighty":10.894285,"marketCap":279079016263.41},{"date":"2026-01-09","current":9.534295,"twenty":8.530036,"median":9.842475,"eighty":10.876951,"marketCap":281377428911.71},{"date":"2026-01-16","current":10.327881,"twenty":8.530036,"median":9.835746,"eighty":10.857459,"marketCap":301858755734.76},{"date":"2026-01-23","current":10.198431,"twenty":8.530036,"median":9.835746,"eighty":10.845279,"marketCap":298327517461.79},{"date":"2026-01-30","current":9.860734,"twenty":8.530036,"median":9.821374,"eighty":10.833289,"marketCap":298603364827.03},{"date":"2026-02-06","current":10.637434,"twenty":8.530036,"median":9.821374,"eighty":10.80613,"marketCap":313859436118.34},{"date":"2026-02-13","current":13.309926,"twenty":8.530036,"median":9.821374,"eighty":10.80613,"marketCap":322679691855.59},{"date":"2026-02-20","current":12.819708,"twenty":8.530036,"median":9.821374,"eighty":10.80613,"marketCap":305795987508.04},{"date":"2026-02-27","current":13.48979,"twenty":8.530036,"median":9.821374,"eighty":10.80613,"marketCap":319159438097.15},{"date":"2026-03-06","current":12.396499,"twenty":8.530036,"median":9.821374,"eighty":10.80613,"marketCap":290370625620.55},{"date":"2026-03-13","current":11.885122,"twenty":8.530036,"median":9.821374,"eighty":10.80613,"marketCap":275846668111.07},{"date":"2026-03-20","current":11.726418,"twenty":8.530036,"median":9.821374,"eighty":10.80613,"marketCap":274144947508.33},{"date":"2026-03-27","current":12.019138,"twenty":8.530036,"median":9.821374,"eighty":10.80613,"marketCap":278207544709.07}],"updateTime":1774712795392},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"TM\",pageSize:20,pageCount:6,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2620870499","title":"Press Release: Kyntra Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2620870499","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620870499?lang=en_us&edition=fundamental","pubTime":"2026-03-17 04:02","pubTimestamp":1773691320,"startTime":"0","endTime":"0","summary":"-- Phase 2 monotherapy trial of FG-3246, a potential first-in-class antibody. prostate cancer  is actively enrolling and remains on track for. -- Positive results from the investigator-sponsored study of FG-3246 in. combination with enzalutamide in patients with mCRPC, further validating. key Phase 2 monotherapy design elements, were presented at the 2026 ASCO. \"The encouraging results from the investigator-sponsored combination trial of FG-3246 with enzalutamide provide us with valuable insights and reinforce key design elements in our Phase 2 monotherapy study,\" said Thane Wettig, Chief Executive Officer of Kyntra Bio. \"Our Phase 2 monotherapy trial of FG-3246 is progressing as planned, with interim results expected in the second half of 2026. Additionally, we have submitted the Phase 3 trial protocol for roxadustat for the treatment of anemia in patients with LR-MDS and expect feedback from the FDA shortly, with the intention to start a Phase 3 trial in the second half of 2026. With","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2236285917.USD","R","BK4099","LU0128525689.USD","LU1267930490.SGD","LU0052756011.USD","LU1267930227.SGD","LU0310800965.SGD","BK4080","DD","BK4604","KYNB","BK4588","BK4109","BK4504","BK4022","TM","BK4139","03160","BK4585","BK4231","ADC","BK4555","LU0310799852.SGD","BK4232","LU0211328371.USD","LU0211327993.USD"],"gpt_icon":0},{"id":"2620499862","title":"Press Release: Rafael Holdings Reports Second Quarter Fiscal 2026 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2620499862","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620499862?lang=en_us&edition=fundamental","pubTime":"2026-03-17 04:01","pubTimestamp":1773691260,"startTime":"0","endTime":"0","summary":"NEWARK, N.J., March 16, 2026  -- Rafael Holdings, Inc.  today reported its financial results for the second quarter fiscal year 2026 ended January 31, 2026.\"We remain pleased with the progress of our pivotal Phase 3 TransportNPC study evaluating Trappsol Cyclo for the treatment of Niemann-Pick Disease Type C1, which the Data Monitoring Committee  recommended continuing after their review of prespecified safety and efficacy data at 48 weeks. We believe that Trappsol Cyclo could provide an important new treatment option for patients suffering from this rare and fatal genetic disease,\" said Howard Jonas, Chief Executive Officer, Executive Chairman and Chairman of the Board of Rafael Holdings.\"We are on track to complete this 96-week Phase 3 clinical trial, the largest ever conducted in this indication, and report preliminary top line results in the third quarter of this calendar year,\" said Joshua Fine, Chief Operating Officer of Rafael Holdings.Research and development expenses were $12.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4604","BK4555","R","RFL","BK4232","BK4099","03160","BK4205","BK4585","BK4588","TM","BK4233","BK4007","BK4022"],"gpt_icon":0},{"id":"2620467786","title":"Toyota turning to China for EVs is impacting more than sales","url":"https://stock-news.laohu8.com/highlight/detail?id=2620467786","media":"Electrek","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620467786?lang=en_us&edition=fundamental","pubTime":"2026-03-17 00:27","pubTimestamp":1773678432,"startTime":"0","endTime":"0","summary":"Toyota may deny it, but it’s increasingly relying on local parts to compete in China’s brutal electric vehicle market. With estimates claiming nearly 90% of parts in some Toyota EVs sold in China are sourced locally, it’s having a bigger impact than expected.","market":"nz","thumbnail":"https://electrek.co/wp-content/uploads/sites/3/2026/03/Toyota-China-EVs.jpeg?quality=82&strip=all&w=1400","type":0,"news_type":0,"thumbnails":["https://electrek.co/wp-content/uploads/sites/3/2026/03/Toyota-China-EVs.jpeg?quality=82&strip=all&w=1400"],"rights":{"source":"electrek_highlight","url":"https://electrek.co/2026/03/16/toyota-china-evs-impacting-more-than-sales/","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://electrek.co/2026/03/16/toyota-china-evs-impacting-more-than-sales/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"electrek_highlight","symbols":["TM"],"gpt_icon":0},{"id":"2619450024","title":"Press Release: Outlook Therapeutics Announces New $18.4 Million Non-Convertible Note Financing and Amendment to Existing Convertible Note","url":"https://stock-news.laohu8.com/highlight/detail?id=2619450024","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619450024?lang=en_us&edition=fundamental","pubTime":"2026-03-16 20:05","pubTimestamp":1773662700,"startTime":"0","endTime":"0","summary":"ISELIN, N.J., March 16, 2026  -- Outlook Therapeutics, Inc. , a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of retina diseases, today announced an amendment to its existing convertible note with Avondale Capital, LLC  and the issuance of a new non-convertible, unsecured note with Atlas Sciences, LLC .Under the amendment to the Existing Note, the maturity date of the Existing Note has been extended to December 31, 2026, with no other changes to the terms. The lender has confirmed that the Existing Note is not in default.In addition, Outlook Therapeutics entered into the $18.4 million New Note. The Company expects to receive $17 million in net proceeds, after original issue discount. Proceeds from the New Note will be used to pay down a portion of the Existing Note, reducing the balance and leaving approximately $10.8 million of principal and interest remaining on the Existing Note.The New Note bears interest at a rate equal to th","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4573","LU0109392836.USD","AMYY","LU1316542783.SGD","LU0889565833.HKD","BK4529","LU1242518931.SGD","LU2931357623.SGD","BK4566","LU1951200564.SGD","IE00BMPRXN33.USD","LU0082616367.USD","LU0056508442.USD","03160","LU1989764664.SGD","OTLK","TM","DAMD","AMDL","BK4612","BK4007","AMDU","AMDD","AMDY","LU0390134368.USD","LU2355687059.USD","LENZ","LU1951198990.SGD","AMUU","BK4604","BK4554","AMDW","LU2458330243.SGD","LU1923623000.USD","LU1880398471.USD","BK4512","LU0719512351.SGD","LU1880398554.USD","LU1988902786.USD","BK4543","BK4588","LU2098885051.SGD","BK4141","LU1064131342.USD","LU0823421333.USD","LU2458330169.SGD","BK4539","BK4534","AMDG"],"gpt_icon":1},{"id":"2619718459","title":"Press Release: Alto Neuroscience Reports Full Year 2025 Financial Results and Recent Business Highlights","url":"https://stock-news.laohu8.com/highlight/detail?id=2619718459","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619718459?lang=en_us&edition=fundamental","pubTime":"2026-03-16 18:03","pubTimestamp":1773655380,"startTime":"0","endTime":"0","summary":"-- Acquisition of ALTO-207 targets Treatment-Resistant Depression  with a clinically-validated mechanism; Phase 2b trial on track to be initiated in the first half of 2026 --. -- External PAX-D study published in The Lancet Psychiatry demonstrated a 0.87 effect size for the core mechanism of ALTO-207; this effect represents a significantly larger effect size than current standard-of-care treatments --. -- ALTO-101 granted FDA Fast Track Designation for CIAS; Topline Phase 2 Proof-of Concept data expected around the end of 1Q 2026 --. --  Acquisition and Accelerated Development of ALTO-207 for TRD: In June. patent coverage of ALTO-207 through at least the mid 204","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4604","BK4588","BK4555","BK4099","TM","BK4007","ANRO","CIAS","BK4585","PIPE","03160"],"gpt_icon":0},{"id":"2619112669","title":"Toyota Hit By Major US Recall Of 550,000 SUVs","url":"https://stock-news.laohu8.com/highlight/detail?id=2619112669","media":"Benzinga_recent_news","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619112669?lang=en_us&edition=fundamental","pubTime":"2026-03-14 02:05","pubTimestamp":1773425100,"startTime":"0","endTime":"0","summary":"Toyota recalls 550k SUVs in the U.S. and slashes Middle East production as Iran-U.S. tensions disrupt exports. Get the TM stock impact.","market":"sh","thumbnail":"https://cdn.benzinga.com/files/images/story/2026/03/13/Mexico-City--Mexico-Marc-2-2024--Toyota-.jpeg?optimize=medium&dpr=2&auto=webp&width=240","type":0,"news_type":0,"thumbnails":["https://cdn.benzinga.com/files/images/story/2026/03/13/Mexico-City--Mexico-Marc-2-2024--Toyota-.jpeg?optimize=medium&dpr=2&auto=webp&width=240"],"rights":{"source":"benzinga_recent_news","url":"https://www.benzinga.com/markets/large-cap/26/03/51249792/toyota-hit-by-major-us-recall-of-550000-suvs","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/markets/large-cap/26/03/51249792/toyota-hit-by-major-us-recall-of-550000-suvs","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"benzinga_recent_news","symbols":["BK4099","03160","TM","BK4585","BK4555","BK4604","BK4588"],"gpt_icon":0},{"id":"2619197740","title":"Press Release: NeOnc Technologies Appoints David Choi as Chief Accounting Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2619197740","media":"Dow Jones","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619197740?lang=en_us&edition=fundamental","pubTime":"2026-03-13 21:00","pubTimestamp":1773406800,"startTime":"0","endTime":"0","summary":"CALABASAS, Calif., March 13, 2026  -- NeOnc Technologies Holdings, Inc.  , a multi-Phase 2 clinical-stage biopharmaceutical company developing novel therapies for central nervous system  cancers, has appointed David Choi as Chief Accounting Officer. In this role, Mr. Choi is responsible for overseeing the Company's accounting, financial reporting, internal controls, and corporate governance functions as NeOnc advances its clinical-stage biotechnology platform and expands its global operations.\"David's extensive expertise in technical accounting and financial reporting for public companies comes at a pivotal time for NeOnc,\" said Amir Heshmatpour, Chairman and CEO of NeOnc. \"As we accelerate our clinical trials and prepare for the next stages of corporate growth, maintaining rigorous financial controls and governance is essential. David's proven track record at top-tier advisory firms makes him an invaluable addition to our leadership team as we strive to deliver novel therapies to pati","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4135","BK4007","BK4500","BK4585","LU1236620750.USD","IND","TM","CNS","NTHI","BK4588","BK4555","CPA","BK4008","03160","BK4099","BK4604","LU1236620834.HKD"],"gpt_icon":0},{"id":"2619993641","title":"Press Release: AC Immune Reports Full Year 2025 Financial Results and Provides a Corporate Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2619993641","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619993641?lang=en_us&edition=fundamental","pubTime":"2026-03-13 19:00","pubTimestamp":1773399600,"startTime":"0","endTime":"0","summary":"-- Phase 2 interim results suggest treatment with active immunotherapy. ACI-7104 may slow the progression of Parkinson's disease. -- NLRP3 inhibitor ACI-19764 Phase 1 trial initiated with first participants. of the AD3 cohort in the Phase 2 ABATE trial of ACI-24 in Alzheimer's. disease in H1 2026, and full 24-month data from Part 1 of the Phase 2. funding to the end of Q3 2027 before any potential milestone payments. Dr. Andrea Pfeifer, CEO of AC Immune SA, commented: \"We made significant progress towards delivering precision prevention of neurodegenerative diseases in 2025, exemplified by the exceptional interim data from the VacSYn trial of ACI-7104, our wholly-owned active immunotherapy targeting <ALPHA>-synuclein. Evidence that ACI-7104 appears to slow the rate of progression in early Parkinson's disease  further demonstrates the potential for active immunotherapies as disease-modifying treatments with the potential to slow or prevent neuronal damage.\". Phase 2 VacSYn trial of our ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AD","ACIU","BK4023","BK4232","BK4585","BK4099","BK4132","BK4588","LU1169590202.USD","BK4022","03160","BK4555","BK4104","BK4113","ACI","IND","R","CAPS","PD","BK4139","LU1169589451.USD","TM","BK4604"],"gpt_icon":0},{"id":"2619993351","title":"Press Release: Better Home & Finance Holding Company Announces Fourth Quarter 2025 Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2619993351","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619993351?lang=en_us&edition=fundamental","pubTime":"2026-03-13 19:00","pubTimestamp":1773399600,"startTime":"0","endTime":"0","summary":"Better exceeds prior guidance on Tinman AI Platform Funded Loan Volume , reiterates guidance, and establishes Q1 2026 outlook. --  In Q4 2025, Funded Loan Volume grew 56% year over year versus industry. growth of 4%, while revenue grew 77% year over year. up 34% quarter-over-quarter, representing more than 40% of Funded Loan. Volume, and exceeding prior guidance of $600 million. 100% month-over-month throughout Q4 in initial rollout to less than 1% of. partners' combined customer base of over 150 million customers. --  Introducing Q1 2026 guidance and reaffirming the previously stated. outlook for Loan Volume and Adjusted EBITDA breakeven. \"The fourth quarter was about positioning the Company for a material ramp in Funded Loan Volume. The early data speaks for itself as we transition from a D2C originator to an AI-native lending platform with rapidly expanding distribution,\" said Vishal Garg, CEO and Founder of Better. \"With the Tinman AI platform and several landmark partnerships scal","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4587","BETR","BK4229","BETRW","BK4022","BK4232","TM","BK4551","03160","AIYY","AI","BK4585","BK4555","BK4604","R","BK4543","BK4528","BK4099","BK4023","BK4588"],"gpt_icon":0},{"id":"2619167719","title":"Press Release: Genenta, Evolving into Saentra Forge, Announces CEO's Appointment by the Italian Government to the Board of Guarantors of the Italian Academy at Columbia University","url":"https://stock-news.laohu8.com/highlight/detail?id=2619167719","media":"Dow Jones","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619167719?lang=en_us&edition=fundamental","pubTime":"2026-03-13 17:00","pubTimestamp":1773392400,"startTime":"0","endTime":"0","summary":"MILAN, March 13, 2026  -- Genenta Science S.p.A.  transforming to Saentra Forge  , a strategic industrial consolidator focused on biotech, defense, aerospace, and Italian national-security-related technologies, today announced that Pierluigi Paracchi, CEO of the Company, has been appointed as a member of the Board of Guarantors of the Italian Academy for Advanced Studies in America, the prestigious center for advanced scholarship hosted at Columbia University in New York, dedicated to promoting Italian culture, research, and intellectual exchange between Italy and the United States.The appointment was conferred by Deputy Prime Minister and Foreign Minister Antonio Tajani and transmitted by the Ambassador of Italy to the United States, Marco Peronaci. The Board of Guarantors is composed of twelve members: six appointed by the Italian Government and six by Columbia University.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4588","BK4604","GNTA","03160","BK4585","BK4099","TM","BK4555"],"gpt_icon":0},{"id":"2619572153","title":"Press Release: Inside information: Timo Lehtonen takes on a new role at Bioretec as External Executive Advisor and steps down from the management team","url":"https://stock-news.laohu8.com/highlight/detail?id=2619572153","media":"Dow Jones","labels":["executive","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619572153?lang=en_us&edition=fundamental","pubTime":"2026-03-13 00:08","pubTimestamp":1773331680,"startTime":"0","endTime":"0","summary":"Bioretec Ltd Inside information 12 March 2026 at 4:30 p.m. EET. TAMPERE, Finland, March 12, 2026 /PRNewswire/ -- Timo Lehtonen, the current Chief Technology Officer of Bioretec Ltd , will transition to the role of External Executive Advisor  and step down from the Company's management team and Chief Technology Officer role as of 6 July 2026.In this non-executive role, Lehtonen will support the Company as an external advisor, providing strategic advice on materials science, technology development, the product pipeline, and clinical and regulatory strategy. He will also support the Company in key external interactions with regulators, investors, partners and key opinion leaders, and help ensure continuity of technological expertise during the leadership transition.Lehtonen has indicated that he intends to participate in Bioretec's planned rights issue announced by the Company on 10 March 2026.As part of this transition, Bioretec will not be replacing the Chief Technology Officer role on ","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03160","BK4604","TM","BK4585","BK4555","BK4099","BK4588"],"gpt_icon":0},{"id":"2618113223","title":"Press Release: MindWalk Holdings Corp. Reports Q3 Fiscal 2026 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2618113223","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618113223?lang=en_us&edition=fundamental","pubTime":"2026-03-12 20:31","pubTimestamp":1773318660,"startTime":"0","endTime":"0","summary":"Third Consecutive Quarter of Year-Over-Year Revenue Growth | First Annual Enterprise LensAI Platform Contract | Launch of B cell Llama Nanobody Discovery Platform. MindWalk Holdings Corp. , a Bio-Native AI company focused on biologics discovery and AI-driven drug development, today reported financial results for the third quarter of fiscal year 2026, ended January 31, 2026. MindWalk will host its Q3 Fiscal 2026 Earnings Call today at 10:30 AM Eastern Time.\"This quarter, MindWalk reported its third consecutive year-over-year revenue increase and advanced three pipeline programs toward data readouts. US revenue doubled year over year, reflecting our deliberate, strategic focus on North America, including the establishment of biologics services operations in the Boston and Cambridge area and ongoing commercial investment in that market. Recently, our largest enterprise AI client signed a one-year LensAI platform contract, the first of its kind for us. LensAI is actively being rolled out a","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4023","TM","BK4551","HYFT","AIYY","BK4587","BK4585","BK4604","03160","BK4232","BK4528","AI","BK4121","BK4588","BK4555","BK4022","BK4543","BK4099","R"],"gpt_icon":0},{"id":"2618131062","title":"Press Release: Cognyte to Announce Fourth Quarter and Full Year FYE26 Financial Results on March 25, 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2618131062","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618131062?lang=en_us&edition=fundamental","pubTime":"2026-03-12 20:10","pubTimestamp":1773317400,"startTime":"0","endTime":"0","summary":"Cognyte Software Ltd. , a global leader in investigative analytics software, today announced it will conduct a conference call on Wednesday, March 25, 2026, at 8:30 a.m. ET to review its fourth quarter and full-year fiscal 2026 financial results for the quarter ending January 31, 2026. An earnings press release will be issued prior to the conference call.A real-time webcast of the conference call with presentation slides will be available in the Investor Relations section of Cognyte's website. Those interested in participating in the question-and-answer session need to register here to receive the dial-in numbers and unique PIN to access the call seamlessly. It is recommended that you join 10 minutes prior to the event start .","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","CGNT","03160","BK4023","BK4585","BK4604","BK4555","TM","BK4099"],"gpt_icon":0},{"id":"2618131733","title":"Press Release: Theriva(TM) Biologics Reports Full-Year 2025 Operational Highlights and Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2618131733","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618131733?lang=en_us&edition=fundamental","pubTime":"2026-03-12 20:01","pubTimestamp":1773316860,"startTime":"0","endTime":"0","summary":"- Licensed SYN-020 to Rasayana Therapeutics for development in multiple indications; up to $38 million in potential milestones plus royalties on commercial sales -. - Cash and cash equivalents of $13.1 million as of December 31, 2025; recent capital raises increase cash to $15.2 million as of February 26, 2026 and provides cash runway into Q1 2027-. ROCKVILLE, M.D., March 12, 2026  -- Theriva Biologics, Inc. , a diversified clinical-stage company developing therapeutics designed to treat cancer and related diseases in areas of high unmet need, today reported financial results for the full year ended December 31, 2025, and provided a corporate update.-- As recently announced, Theriva received positive scientific advice from. the EMA on the design of a Phase 3 trial in PDAC. The EMA provided. overall agreement with the proposed Phase 3 clinical trial of VCN-01 in. of metastatic PDAC, including sample size, repeated dosing of VCN-01, and. an adaptive design to potentially optimize trial t","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TOVX","BK4139","BK4099","BK4588","BK4555","TM","BK4604","BK4585","03160"],"gpt_icon":0},{"id":"2618213178","title":"Press Release: MBX Biosciences Reports Fourth Quarter and Full-Year 2025 Financial Results and Recent Corporate Highlights","url":"https://stock-news.laohu8.com/highlight/detail?id=2618213178","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618213178?lang=en_us&edition=fundamental","pubTime":"2026-03-12 20:00","pubTimestamp":1773316800,"startTime":"0","endTime":"0","summary":"Phase 3 trial of once-weekly canvuparatide remains on track to initiate in Q3 2026 following recently completed, successful End-of-Phase 2 meeting with FDA. 12-week MAD Phase 1 data from MBX 4291 for obesity anticipated in Q4 2026. Planned nomination of amycretin and GLP-1/GIP/glucagon receptor triple-agonist development candidates for obesity expected in Q2 and Q3 2026. $459.1 million in pro forma cash and investments as of December 31, 2025, including $85.4 million in net proceeds from top-tier institutional investors through ATM program; expected to support operations into 2029. \"2025 was a year of continued growth and execution for MBX, highlighted by the clinical validation of our Precision Endocrine Peptide  platform,\" said Kent Hawryluk, President and Chief Executive Officer of MBX Biosciences. \"Following a successful End-of-Phase 2 meeting with the FDA, we now have a clear path to initiate our Phase 3 trial of once-weekly canvuparatide. We are also advancing a growing obesity p","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4604","BK4588","MBX","BK4555","BK4099","PBH","BK4092","BK4007","TM","HP","BK4585","03160"],"gpt_icon":0},{"id":"2618131761","title":"Press Release: Century Therapeutics Reports Full Year 2025 Financial Results and Business Updates","url":"https://stock-news.laohu8.com/highlight/detail?id=2618131761","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618131761?lang=en_us&edition=fundamental","pubTime":"2026-03-12 20:00","pubTimestamp":1773316800,"startTime":"0","endTime":"0","summary":"-- CNTY-813, lead beta islet cell therapy program as a potential functional. cure for type 1 diabetes, in Investigational New Drug -enabling. studies; IND submission expected in 4Q 2026 to support anticipated. -- CNTY-308, a CD19-targeted CAR-iT cell therapy engineered with. Allo-Evasion 5.0, on track to enter the clinic in 2026. -- Strengthened balance sheet and cash runway extended into 1Q 2029 from. PHILADELPHIA, March 12, 2026  -- Century Therapeutics, Inc. , a biotechnology company developing induced pluripotent stem cell -derived cell therapies for autoimmune diseases, including type 1 diabetes, and cancer, today reported financial results for the full year ended December 31, 2025, and recent business highlights.-- CNTY-813, priority program for type 1 diabetes, advancing through. 2026: Century continues to advance IND-enabling studies for its lead. pipeline program, CNTY-813, a beta islet replacement therapy with. To date, Century has generated compelling preclinical data for CN","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","BK4139","BK4539","03160","BK4505","BK4585","BK4604","IPSC","BK4555","TM","BK4099","IND"],"gpt_icon":0},{"id":"2618213946","title":"Press Release: Helus Pharma Strengthens Executive Team with Appointment of Jill Conwell as Chief People Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2618213946","media":"Dow Jones","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618213946?lang=en_us&edition=fundamental","pubTime":"2026-03-12 19:30","pubTimestamp":1773315000,"startTime":"0","endTime":"0","summary":"-- Proven human resources and organizational strategist brings more than two. -- Appointment supports Helus Pharma's continued maturation as the company. NEW YORK and TORONTO, March 12, 2026  -- Helus Pharma  , a clinical stage pharmaceutical company committed to helping minds heal by developing novel serotonergic agonists , today announced the appointment of Jill Conwell as Chief People Officer, effective immediately.\"Jill has a proven ability to help life sciences companies build and align teams, organizational strategies, and processes to support ambitious growth,\" said Michael Cola, Chief Executive Officer of Helus Pharma. \"As Helus Pharma advances our clinical programs and prepares for the next phase of growth, Jill's experience will be invaluable in helping us attract top talent, advance our culture, and scale the organization to support the business.\". Helus Pharma, the commercial operating name of Cybin Inc.  is a clinical stage pharmaceutical company committed to helping minds","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03160","BK4099","BK4604","TM","TISI","BK4585","BK4588","BK4555","BK4120"],"gpt_icon":0},{"id":"2618133917","title":"Press Release: HLS Therapeutics Announces Fiscal 2025 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2618133917","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618133917?lang=en_us&edition=fundamental","pubTime":"2026-03-12 18:30","pubTimestamp":1773311400,"startTime":"0","endTime":"0","summary":"-- Adjusted EBITDA1 grew 18% to $19.6 million in fiscal 2025. -- Cash from operations grew 114% to $17.1 million in fiscal 2025. -- In-licensed NILEMDO and NEXLIZET for the Canadian market; NILEMDO. approved by Health Canada in November 2025 and is now commercially. -- Announced new credit facility with lower rates, increased flexibility and. reduced F/X risk; reduced long term debt by 26%, achieving 43% reduction. TORONTO, March 12, 2026 /CNW/ - HLS Therapeutics Inc.  , a pharmaceutical company focused on addressing unmet needs in the treatment of psychiatric disorders and cardiovascular disease, announces its financial results for the three and twelve months ended December 31, 2025 . All amounts are in thousands of United States  dollars unless otherwise stated.and cash from operations was $17.1 million, compared to $56.6 million,-- Canadian product sales increased 1.5% in fiscal 2025 in local currency. -- U.S. Clozaril sales decreased 1.6% in fiscal 2025, an improvement from. the pr","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","BK4232","BK4539","BK4585","BK4555","R","BK4022","BK4099","BK4604","BK4139","03160","BK4588","TM","LENZ"],"gpt_icon":0},{"id":"2618487971","title":"Press Release: MariMed Reports Fourth Quarter and Full Year 2025 Earnings","url":"https://stock-news.laohu8.com/highlight/detail?id=2618487971","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618487971?lang=en_us&edition=fundamental","pubTime":"2026-03-12 06:34","pubTimestamp":1773268440,"startTime":"0","endTime":"0","summary":"NORWOOD, Mass., March 11, 2026  -- MariMed Inc.   , a leading multi-state cannabis operator focused on improving lives every day, today announced its financial results for the fourth quarter and year ended December 31, 2025.Despite continued pricing pressure across many cannabis markets, the Company generated revenue growth and positive Adjusted EBITDA for the sixth consecutive year, reflecting the strength of its branded product portfolio and disciplined operational execution.-- Sixth consecutive year of positive Adjusted EBITDA. \"Looking ahead to 2026, we have a number of drivers to fuel our growth. These include: a full year of financial contribution following the launch of adult-use cannabis sales in Delaware last August and the launch of our brand distribution in Maine through a new licensing partner during the fourth quarter of 2025; and revenue generated by the new Columbus, Ohio, dispensary we intend to open during the year.\". The following table summarizes the Company's consol","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","BK4099","TM","BK4555","MRMD","BK4585","BK4588","BK4604","03160"],"gpt_icon":0},{"id":"2618979591","title":"Press Release: SIR Royalty Income Fund Announces March 2026 Distribution","url":"https://stock-news.laohu8.com/highlight/detail?id=2618979591","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618979591?lang=en_us&edition=fundamental","pubTime":"2026-03-12 05:35","pubTimestamp":1773264900,"startTime":"0","endTime":"0","summary":"BURLINGTON, ON, March 11, 2026 /CNW/ - SIR Royalty Income Fund   today declared a cash distribution of $0.105 per unit for the period February 1, 2026 to February 28, 2026. The distribution will be payable on March 31, 2026 to unitholders of record as at the close of business on March 20, 2026.SIR Corp.  is a privately held Canadian corporation that owns a portfolio of 54 restaurants in Canada. SIR's Concept brands include Jack Astor's Bar and Grill with 36 locations and Scaddabush Italian Kitchen & Bar with 14 locations. SIR also operates one-of-a-kind Signature brands including The Loose Moose, Reds Square One and Edna + Vita . All trademarks related to the Concept and Signature brands noted above are used by SIR under a License and Royalty Agreement with SIR Royalty Limited Partnership. SIR also owns one Duke's Refresher + Bar location, which is currently not part of the Royalty Pool. For more information on SIR or the SIR Royalty Income Fund, please visit www.sircorp.com.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4555","BK4604","BK4232","R","BK4099","BK4588","BK4022","TM","BK4585","SIR","03160"],"gpt_icon":0}],"pageSize":20,"totalPage":20,"pageCount":6,"totalSize":400,"code":"91000000","status":"200"}]}}